Statins linked to reduced risk of death from COVID-19 in major population study
Statins are a recommended and common intervention for preventing cardiovascular events by reducing levels of lipoprotein cholesterol in the blood. During the pandemic, it has been debated whether statins influence the risk of death from COVID-19. Researchers at Karolinska Institutet have now conducted the largest population study to date in the field. The study, which is published in PLOS Medicine, indicates that statin treatment slightly lowers COVID-19 mortality.
Statins are used to lower the cholesterol level – the lipid count – in the blood and are a common preventative treatment in patients at high risk of cardiovascular events.
During the pandemic, the question of whether statins can reduce COVID-19 mortality via their effects on coagulation and the immune system has engaged scientists and doctors.
Earlier studies have not provided an unequivocal answer and have often suffered from the limitation that they have only included hospital inpatients. Researchers at Karolinska Institutet have now carried out the largest population study to date on the relationship between statins and COVID-19 mortality.
Release date: 14 October 2021
Source: Karolinska Institutet